

ASX Release

EMVision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

AGM – CHAIRMAN’S ADDRESS & CEO PRESENTATION

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”) announces the following Chairman’s Address and CEO Presentation to be provided to shareholders at the Company’s Annual General Meeting to be held at 10.00am at Level 10, 12 Creek Street, Brisbane QLD 4000 on 26 November 2019.

Chairman’s Address to Shareholders

Over the last year, EMVision has grown from strength to strength and made pleasing progress against our key milestones. In particular, the completion of our first clinical portable brain scanner represents a breakthrough opportunity for imaging the brain, at the point of care, in a manner otherwise not possible today. We look forward to validating our technology in the clinic during the days ahead and tackling the global health economic burden that is Stroke. The market opportunity and unmet clinical need for an imaging device such as ours are truly compelling.

During the year we announced several new additions to the EMVision team, including Ruth Cremin as head of regulatory and quality affairs and the formation of a Clinical Advisory Board comprising an expert panel of clinical advisors.

Ruth has delivered a number of successful FDA, CE and TGA clearances, and brings a proven track record to the company to drive our regulatory strategy and engagement with the FDA, which is already underway.

Our recently appointed Clinical Advisory Board, chaired by Prof Stuart Crozier, comprises leaders in their respective fields of neurology, radiology and intensive care. Each will contribute to our future success.

I’d like to thank our excellent collaborators and partners for their efforts throughout the year. The University of Queensland, Princess Alexandra Hospital, GE Healthcare, the Australian Stroke Alliance and Keysight Technologies have all made valuable contributions to our technology, product and clinical development. I would also like to acknowledge the ongoing financial assistance provided by the Department of Innovation, Industry and Science.

As we move into 2020 we will continue to explore commercial and product development partnerships that add long-term value to the Company.

Early this month we successfully completed a \$4.5M capital raise that was strongly supported by Australian and International institutional and professional investors. The funds will be used to support commercial product development of the Company’s breakthrough portable brain scanner, clinical studies and for working capital.

Finally, I take this opportunity to thank my fellow directors and the hard working EMVision team for their exceptional efforts in making the last year one of fantastic progress and product advancement for the Company and its shareholders.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.9 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



CEO PRESENTATION

Annual General Meeting

Dr Ron Weinberger
November 2019



DISCLAIMER

This presentation has been prepared by Emvision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in EMVision in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors.

Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation.


Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of EMVision. To the maximum extent permitted by law, EMVision and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

An investment in EMVision securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of EMVision. EMVision does not guarantee any rate of return or the absolute or relative investment performance of EMVision securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

EMV IS DEVELOPING BREAKTHROUGH PORTABLE DIAGNOSTICS

- + Portable
- + Non-ionising
- + Miniaturized hardware
- + Cost Effective
- + Non-invasive
- + Powerful functional imaging capabilities

Electromagnetic Radio Frequency (RF) is a truly **innovative imaging modality** that has disruptive implications for diagnostics, monitoring and the delivery of care in the future



The application and capabilities of electromagnetic microwave biomedical imaging for the brain, torso and skin is subject to successful clinical investigation. The EMVision device pictured is for Neurological applications only.

TEAM

Significant experience developing and commercialising medical devices



Dr Ron Weinberger
Chief Executive Officer

Former Exec Director / CEO of Nanosonics (ASX: NAN), \$2BN market cap company

20 yrs experience developing and commercialising medical devices



John Keep
Executive Chairman

Former CEO of Queensland Diagnostic Imaging (\$109M Trade sale to Mayne Pharma)

Over 30 yrs senior executive leadership and M&A experience



Scott Kirkland
Executive Director

Co-founder of EMvision Medical Devices Ltd

Experienced corporate affairs, capital markets and technology sales executive



Prof Stuart Crozier
Clinical Development Advisor

Co-inventor of underlying technology

Globally renowned for MRI advancements (70% installed hold Stuart's patents)



Robert Tiller
Product Design & Development Executive

CEO and Founder of Tiller Design (product developer for ResMed and Nanosonics)

25 yrs experience in medical device design, development and commercialisation



Geoff Pocock
Non-Executive Director

Former Managing Director / Co-Founder of Hazer Group (ASX: HZR)

20 yrs experience commercialising emerging technologies and capital markets



Tony Keane
Non-Executive Director

Over 30 years finance experience in business, corporate and institutional banking

Advisory Board and NED roles including ASX 200 company National Storage REIT (ASX:NSR)



Ryan Laws
Non-Executive Director

Co-founder of EMvision Medical Devices Ltd

Experienced corporate advisor & investor



Emma Waldon
Company Secretary
Chartered Accountant

Diverse capital markets & corporate governance experience



Dr. Konstanty Bialkowski
Head of Tech Development
Co-inventor of underlying technology

Expert in near-field biomedical radar, microwave imaging and signal processing techniques.



Ruth Cremin
Head of Quality & Regulatory Affairs
Former Head of Quality and Regulatory at Nanosonics (ASX:NAN) and Snr Regulatory Specialist at Cochlear (ASX:COH)
Multiple successful FDA, TGA and CE mark clearances.

CLINICAL ADVISORY BOARD

EMvision has secured advisors with world-leading experience in diagnosing and treating neurological disorders. The composition and Brisbane location of the group has been specifically engineered to aid in delivering a successful clinical trial program.




Prof Stuart Crozier
Co-Inventor

“ It is a pleasure to be involved with this Clinical Advisory Board. EMvision has assembled a set of very talented and experienced clinicians in the fields of Neurology, Interventional Neuroradiology and Critical Care. The board will no doubt grow in the future as the clinical targets expand. It is critically important that the clinical need drives the directions of the technology and not the other way around, in my view. The board will have a very important role in this regard as EMvision develops its new modality for diagnostic imaging. ”




Dr. Ken Mitchell
*Interventional
Neuroradiologist*

“ In recent years, reperfusion therapies such as thrombolysis and endovascular thrombectomy for ischaemic stroke have dramatically reduced disability and transformed stroke management. These advances in stroke care have greatly increased the demand on interventional medical services and have highlighted the need for rapid, portable imaging, for better acute evaluation of the patient. I look forward to better outcomes for our patients by identifying those most suitable for the new treatments now available earlier. ”



Dr. David Cook
Snr Critical Care Specialist

“ The last two years has seen EMvision technology advancing us towards the realisation of a novel imaging technology that will assist medical practitioners in making critical decisions, and critical interventions earlier, when time matters. ”



**Prof Michael
O'Sullivan**
Neurologist

“ Many strokes occur far from a specialist centre. A new phase will see mobile and portable technology move to the patient. We need advanced solutions beside the patient at the time of stroke, so that treatments can be delivered within the community without delay, and so that we can rapidly identify those patients that need to go to a centre. That vision of technology reaching patients wherever they are, on a global scale, is the reason I'm so excited to be part of EMvision. ”



Dr. James Walsham
Senior Staff Specialist

“ I'm excited to be involved in the development of EMvision's potentially disruptive new technology. ”

”



2019 HIGHLIGHTS



CLINICAL UNIT BUILD COMPLETE

System integrated, built and tested by a broad range of clinicians for hospital workflow suitability and usability.



ETHICS CLEARANCE AND SAFETY

Includes both **operator and patient safety** as well as ensuring no interference with other medical devices.



TEAM STRENGTHENED

Hired **Ruth Cremin**, former Head of Regulatory & Quality at ASX:NAN to lead our global regulatory strategy. Planning further strategic hires.



VALUE ADD PARTNERSHIPS

Partnership with **Keysight** for development of a low cost, small footprint VNA. Joined **The Australian Stroke Alliance** for clinical input and MRFF funding application in 2020.



NEW IP GENERATED

Further **algorithm advancements**. New IP generated in hardware and software integration providing strong protection.



WELL CAPITALISED

Recent placement of \$4.5M, proforma cash on hand at 30 Sep 2019 of \$7.3M (including placement net of share issue costs), additional funding expected from FY19 R&D tax rebate and CRC-P grant contributions.

2019 COLLABORATION UPDATE



- + Collaboration **continues to strengthen** in preparation for a Stage 2 Frontiers Bid anticipated for early next year.
- + Stage 2 grants are pledged by the MRFF at **\$50 million** or more per group and can last up to five years. If successful, Stage 2 could contribute to funding clinical trials and our first responder product development.
- + The groups' vision is to develop world-first technologies that will radically transform access to early **pre-hospital stroke care**.
- + An Australian Stroke Alliance consortium recently visited Brisbane to spend time with EMV management, our technology team and our clinical collaborators.



- + The team **continues to make excellent progress** towards a compact and cost effective healthcare personalised Vector Network Analyst (VNA) for EMV's planned commercial product.
- + **Keysight (NYSE:KEYS)** sent **Senior R&D personnel from the US to provide on ground support** during the commissioning phase of our VNAs for our upcoming clinical trial.
- + Key members of their **Senior Executive team will be visiting EMVision and the PA Hospital in December**, highlighting their commitment to our collaboration.




- + **EMVision joined the NVIDIA Corporation (NASDAQ:NVDA) Inception Program**, an accelerator program that helps companies during critical stages of product development, prototyping and deployment.
- + EMVision will gain access to resources and expertise to **accelerate its AI-based functions for enhanced image reconstruction**.
- + Additional program benefits may also include grants and go-to-market support.

CLINICAL TRIAL PROGRESSING TO PLAN

The purpose of the initial clinical trial is to gather information from stroke patients that allows refinement and selection of the optimal imaging algorithms as well as early data on correlation with CT and/or MRI


FIRST UNIT INTERNAL VERIFICATION, EMC TESTING COMPLETE

Internal testing complete for first device to enter the Hospital environment and shortly receive electrical safety tagging




CLINICAN TRAINING UNDERWAY

Clinician and nursing staff have commenced preliminary training with the clinical prototype



ADDITIONAL SUPPORTING CLINICAL UNITS NEAR COMPLETION

A further two supporting units are being fabricated



PATIENT SCANNING ANTICIPATED TO COMMENCE IN DECEMBER

Including formal clinical trial green light and stroke patient scanning



2020 TARGET MILESTONES

Over next 6-12 Months

Feedback from initial FDA pre-submission and development of regulatory approval plan

Pilot-clinical trial read-outs

Australian Stroke Alliance non-dilutive funding outcome for first-responder model of portable brain scanner

Further value-add product development and commercial partnerships

Building of in-house engineering team

Development of commercial units of portable brain scanner for pivotal clinical trial

Pivotal clinical trial site selection

Development of manufacturing strategy

Further strategic employee hires

www.emvision.com.au

GET IN TOUCH



Dr Ron Weinberger
CEO, EMvision
E: rweinberger@emvision.com.au
P: 02 8667 5337

Scott Kirkland
Executive Director, EMvision
E: skirkland@emvision.com.au
P: 02 8667 5337